Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
2023
Michael A. Postow, Susan J. Knox, Debra A. Goldman, Yuval Elhanati, Vikram Mavinkurve, Phillip Wong, Darragh Halpenny, Sunil K. Reddy, Kenya Vado, Danielle McCabe, Kristen Aufiero Ramirez, Mary Macri, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Parisa Momtaz, Alexander N. Shoushtari, Margaret K. Callahan, Paul B. Chapman, Jedd D. Wolchok, Priyanka B. Subrahmanyam, Holden T. Maecker, Katherine S. Panageas, Christopher A. Barker
Abstract
<p>Additional description of correlative immunologic assays</p>
Related Papers
- → Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain(2018)1,297 cited
- → Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)(2019)100 cited
- → Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection(2019)11 cited
- → <p>Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date</p>(2019)11 cited
- → Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma(2019)2 cited